Assessing the quality of bowel preparation by addition of Movicol to standard bowel preparation regimen in patients undergoing routine colonoscopy: a randomized controlled trial

Phase 3

• Conditions: Cancer - Bowel - Anal; Gastrointestinal; Cancer - Bowel - Back passage (rectum) or large bowel (colon)

• Registration Number: ACTRN12616000712404
• Lead Sponsor: Alfred Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-30
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 362

Inclusion Criteria

Consenting adult patients referred for outpatient colonoscopy procedure for clinically accepted indications (these generally include but are not restricted to iron deficiency anaemia, surveillance of bowel polyps, colorectal cancer screening, assessment of symptoms such as abdominal pain, diarrhoea and constipation, assessment or investigation of inflammatory bowel disease)

Exclusion Criteria

Exclusion criteria are as follows:
Conditions which are exclusions to colonoscopy in normal clinical practice (suspected bowel perforation, gastric outlet obstruction, toxic megacolon, severer colitis, pregnancy or lactation)
Significant renal failure (eGFR<30)
Significant heart failure (New York Heart Association Class III or IV)
Type 1 diabetes
Cystic fibrosis
Phenylketonuria (Prepkit C contraindicated)
Known hypersensitivity to a constituent of Picoprep, Glycoprep or Picosalax and Movicol
(Type 1 diabetics or Cystic Fibrosis patients are excluded as they follow specific guidelines for bowel preparation for colonoscopy at Alfred Hospital.)

Study & Design

• Study Type: Interventional
• Study Design: Not specified